Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | EPS15 | P42566 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.57 |
| ▸ | ITGAV | P06756 | 1/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.57 |
| ▸ | KDM4A | O75164 | 1/20 | 0.56 |
| ▸ | NECTIN4 | Q96NY8 | 2/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.55 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.55 |
| ▸ | SSTR3 | P32745 | 4/20 | 0.55 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.55 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13254563 | 0.93 | EPS15 (0.61) | PCSK9EPS15NECTIN4KLK5KLKB1 | |
| SCHEMBL24483647 | 0.83 | SLC6A3 (0.85) | PCSK9SLC6A3EPS15ITGB3ITGAV | |
| SCHEMBL29362264 | 0.83 | PCSK9 (0.58) | PCSK9SLC6A3EPS15KDM4ANECTIN4 | |
| SCHEMBL29462281 | 0.82 | SLC6A3 (0.65) | PCSK9SLC6A3ITGB3ITGAVNECTIN4 | |
| SCHEMBL29938261 | 0.79 | SSTR4 (0.81) | SSTR4SSTR3SSTR2SSTR5 | |
| SCHEMBL29693078 | 0.79 | TACR1 (0.62) | KDM4A | |
| SCHEMBL29938084 | 0.79 | SSTR4 (0.81) | SSTR4SSTR3SSTR2SSTR5 | |
| SCHEMBL29938282 | 0.78 | SSTR4 (0.82) | SSTR4SSTR3SSTR2SSTR5 | |
| SCHEMBL29938331 | 0.78 | SSTR4 (0.82) | SSTR4SSTR3SSTR2SSTR5 | |
| SCHEMBL29938207 | 0.78 | SSTR4 (0.82) | SSTR4SSTR3SSTR2SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090668-B2 | Process for synthesizing cyclic peptide compound | THE UNIVERSITY OF TOKYO (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20100168380-A1 | PROCESS FOR SYNTHESIZING CYCLIC PEPTIDE COMPOUND | THE UNIVERSITY OF TOKYO (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168380-A1 | PROCESS FOR SYNTHESIZING CYCLIC PEPTIDE COMPOUND | VIP, NGLY1, QPCT | PCSK9 426/4885SLC6A3 4880/4885EPS15 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.